Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs.

@article{Arslan2012TreatmentWO,
  title={Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs.},
  author={Fatih Arslan and Jaco H. Houtgraaf and Brian Keogh and Kushan Kazemi and Renate de Jong and William J. McCormack and Luke A J O'Neill and Peter McGuirk and Leo Timmers and Mirjam B. Smeets and Lars Akeroyd and Mary M Reilly and G. Pasterkamp and Dominique Paschalis Victor de Kleijn},
  journal={Circulation. Cardiovascular interventions},
  year={2012},
  volume={5 2},
  pages={279-87}
}
BACKGROUND Toll-like receptor (TLR)-2 is an important mediator of innate immunity and ischemia/reperfusion-induced cardiac injury. We have previously shown that TLR2 inhibition reduces infarct size and improves cardiac function in mice. However, the therapeutic efficacy of a clinical grade humanized anti-TLR2 antibody, OPN-305, in a large-animal model remained to be addressed. METHODS AND RESULTS Pigs (n=38) underwent 75 minutes ischemia followed by 24 hours of reperfusion. Saline or OPN-305… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart

  • W. Chao
  • Am J Physiol Heart Circ Physiol
  • 2009

Similar Papers

Loading similar papers…